Who We Are

The Association of Community Health Nursing Educators (ACHNE) provides a meeting ground for those committed to excellence in community and public health nursing education, research, and practice. ACHNE was established in 1978 and is run by elected volunteer leaders who guide the organization in providing networking through the quarterly newsletter and membership directory, and providing educational opportunities through publications and the annual Spring Institute. 

Read More

ACHNE Board Election Now Open!

It is time to cast your vote in the 2017 ACHNE Election. This year you will be choosing a Vice President, Secretary, General Member-at-Large/Chair of Membership Committee, Northern Member-at-Large, Midwest Member-at-Large and Two Nominating Committee Members. View candidate statements and access official ballot. 

posted 3/14/17 delete 4/7/17

ACHNE needs at least 1 volunteer to represent ACHNE on the writing team for the Quad Council Coalition (QCC) White Paper on an environmental health issue (TBD) related to PHN.

Fellow co-authors will include representatives from each of the QCC member organizations, including representatives of the Alliance of Nurses for a Healthy Environment (AHNE), Association of Public Health Nurses (APHN), and PHN section of APHA. If you have an interest in environmental issues and/or working on a joint paper and are available to help the white paper be completed completion this year and are willing to represent ACHNE, please contact me directly at pamela_f_levin@rush.edu. This is a great opportunity for collaborating with fellow PHNs in producing a guidance document for PHN practice!

posted 3/17/17 delete 6/7/17

Hi ACHNE! I wanted to contribute a resource that I hope will be of use to you and your readers! MPH@GW, the online MPH program from The Milken Institute School of Public Health at The George Washington University, recently published a piece on the development of vaccines. It includes several small graphics about: -the differences between immunization and vaccination -the phases of vaccine development -the stakeholders in vaccine production We hope that these resources will help shed some light on how detailed and regulated the process of vaccine development really is. Would you be interested in using any of these resources on your website or social media pages? Please let me know, and I would be happy to provide you with more context around the piece, or the JPEGs of the graphics! Thanks in advance! Julie Potyraj | Community Manager | MPH@GW/HealthInformatics@GW MPH Candidate, Fall 2017 Milken Institute School of Public Health The George Washington University e: jpotyraj@publichealthonline.gwu.edu | t: @GWSPHonline '

posted 3/17/17 delete 4/17/17

ACHNE 2017 Call for Award Nominations

Deadline Extended to March 24th!

Dear ACHNE Member: 

On behalf of the ACHNE Awards Committee,  we are seeking your nominations for the 2017 ACHNE Awards: 

Member Awards:

  1. Outstanding Contributions to Community/Public Health Nursing Education
  2. Outstanding Contributions to Community/Public Health Nursing Practice
  3. Outstanding Contributions to Community/Public Health Nursing Research
  4. Outstanding Service to ACHNE

Student Awards (Membership not required for nomination):

  1. Outstanding Masters Graduate Student in Community/Public Health Nursing
  2. Outstanding Doctoral Graduate Student in Community/Public Health Nursing

This is a wonderful way to honor ACHNE members who are deserving of special recognition. Note that nominators and nominees must be current members of ACHNE as of February 1, 2017.

Submitting nominations is a simple process, with nominations due by 5:00 p.m. Eastern on March 24, 2017.

Click here for award criteria and the nomination form.

Questions and Nomination Submissions may be addressed to: Gail Oneal, Tel. 509-324-7263, Chair of ACHNE Awards Committee

posted 3/17/17 delete 3/25/17

ACHNE 2017 Ballot


Dear ACHNE Member,
It is time to cast your vote in the 2017 ACHNE Election. This year you will be choosing a Vice President, Secretary, General Member-at-Large/Chair of Membership Committee, Northern Member-at-Large, Midwest Member-at-Large and Two Nominating Committee Members. 

Candidates for 2017 Ballot:

Vice President

Lori Edwards, DrPH, MPH, BSN, RN, APHN-BC


Krista Jones, DNP, MSN, APHN, RN

Member-at-Large/Chair of Membership Committee:

Donna M. Kazemi, PhD, RN, CNE, FAAN

Northern Member-at-Large*

Elizabeth A. Campbell, PhD, MSN, FNP, CNE

Karen May, PhD, RN, CNE

Claudia M. Smith, PhD, MPH, RN-BC

Midwest Member-at-Large*

Amber Dallwig, MSN, BSN

Becky Davis, DNP APHN-BC

Nominating Committee (Vote for Two)

Heide R Cygan, DNP, RN, APHN-BC

Susan Harrington, PhD, RN

*Reminder: You are only allowed to vote for Members-at-Large (MALs) for the region in which you live. The Northern Region includes: Connecticut, District of Columbia, Delaware, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont. The Midwest Region includes: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, North Dakota, Ohio, Oklahoma, South Dakota and Wisconsin.

The deadline for voting is Friday, April 7, 2017 at midnight EDT. Please note: You will be required to log in to the members area to view this information. 

If you have questions for the Nominating Committee, please contact the co-chairs, David Reyes or Jennifer Shearer.

Click here to view candidate statements 

posted 3/17/17 delete 4/7/17

New thread has been posted to forum Forums, thread Wanted:

BSN programs to pilot a vignette evaluating student competence using the QC competencies

SSwider on 03/10/2017
Colleagues,  AACN has been collaborating with CDC for the past 4 years to strengthen nursing education in public and population health. One of the endeavors we are engaged in is to begin to develop mechanisms to evaluate whether our teaching strategies are helping our students gain knowledge and skills in PHN, as measured by the QC competencies for generalist practice. To that end, we have developed a short vignette, with questions to assess student competency in a few key areas. We want to pilot this vignette in 4-5 schools, with traditional BSN programs. We need 20 students at the early stages of their nursing program, and 20 students just before graduation, from each program. We will be collecting data in the next 4 weeks. If you are interested in your school's participation, please contact Susan Swider, PhD, APHN-BC, FAAN at susan_m_swider@rush.edu. Thanks for considering. To view the thread go to http://www.achne.org/i4a/bb/index.cfm?page=topic&topicID=29.

Posted 3/17/17 delete 4/17/17

Trump and Federal Prevention Policy

An essay posted by Health Affairs on Tuesday discussed “How the Trump Administration Could Advance Federal Prevention Policy.” The authors, all from the Bipartisan Policy Center, conclude, “Not all existing federal prevention policy will be maintained in a Trump administration. Certainly, regulatory approaches will be the first to be scrutinized and the new leadership would be wise to maintain gains in tobacco control, nutrition, and cancer prevention. Nevertheless, there are additional opportunities, consistent with traditional Republican principles, to support prevention efforts the administration should pursue. To begin, the administration should review the current goals and objectives of Healthy People, which has been utilized by previous administrations for nearly four decades to set 10-year national objectives for improving the health of all Americans. Ultimately, prevention is, and must continue to be, a bipartisan pursuit. The health of Americans and of our health care system demands nothing less.”

The article was co-authored by G. William Hoagland. He is a former staff director of the Senate Budget Committee and will be a speaker at the ASPPH Annual Meeting in a session titled, “Legislative Challenges Facing Academic Public Health.” The session is scheduled for Thursday, March 16, from 3:30-5:00 pm.

posted 3/6/17 delete 3/17/17

Council on Linkages Releases Meeting Schedule for 2017

The Council on Linkages Between Academia and Public Health Practice (Council on Linkages) has scheduled four meetings to be held throughout 2017. Dates and times of the meetings are as follows:

  • Tuesday, April 11th, from 1-3pm ET
  • Monday, July 17th, from 1-3pm ET
  • Monday, October 2nd, from 2-4pm ET
  • Tuesday, December 12th, from 1-3pm ET

These meetings will be held by conference call and will focus on activities related to the Academic Health Department Learning Community, the Core Competencies for Public Health Professionals, and other initiatives of the Council on Linkages. All public health professionals interested in learning more about Council on Linkages initiatives are welcome to attend. Additional information, including agendas and meeting materials, will be available prior to each of these meetings. For more information, please contact Janelle Nichols at jnichols@phf.org.

Posted Feb 28, 2017 Remove December 13, 2017

Secure Your 2017 Sponsorship & Exhibit Space   Secure your spot to join us in Baltimore, MD for the 2017 ACHNE Annual Institute, taking place June 8-10, 2017 at the Lord Baltimore Hotel! Our momentum continues to build from year to year, so don't miss out in 2017, as it's sure to be another great meeting! Click here for the PDF.

Posted Feb 1 Delete Mar 15, 2017


Nursing Community: Activities

ACHNE is a member of the Nursing Community, a coalition of 63 national professional nursing organizations. The NC is a policy and advocacy group, who sends letters to Congress, provides testimony and attends Congressional/Administration meetings on behalf of the membership.
Attached is the NC's 2016 Year in Review
During this time of rapid change in Washington, the NC us working to be a strong and nimble voice for nursing. I will post their letters and advocacy events here, on this discussion board thread, as they come up.

Posted Feb 1 Delete Mar 15, 2017

Clinician Outreach and Communication Activity from CDC

We want to inform you about the following CDC Health Alert Network (HAN) Health Advisory that CDC issued January 24, 2017. Please feel free to share this information with your members.
If you have any questions about this or other clinical issues, please e-mail coca@cdc.gov
On behalf of the Clinician Outreach and Communication Activity (COCA)
Centers for Disease Control and Prevention (CDC)
Join us on Facebook
This is an official
Distributed via the CDC Health Alert Network  January 24, 2017, 14:00 ET (2:00 PM ET)  CDCHAN-00400
Investigation of Seoul Virus Outbreak Associated with Home-based, Rat-breeding Facilities in Wisconsin and Illinois
CDC and health officials from Wisconsin and Illinois are conducting an investigation of Seoul virus infections among pet rats and persons exposed to rats at rat-breeding facilities in Wisconsin and Illinois. Seoul virus is a member of the hantavirus group of rodent-borne viruses. Trace-back and trace-out investigations of possibly infected rodents have identified distribution chains in other states that may require additional investigations. People who become infected with this virus often exhibit relatively mild or no symptoms, but some will develop a form of hemorrhagic fever with renal syndrome (HFRS) with death in approximately 1–2% of HFRS cases. Although serologic studies have indicated the presence of Seoul virus in wild rats in the United States, this is the first known outbreak associated with pet rats in the United States.
As part of the outbreak investigation, CDC and Illinois and Wisconsin health officials are conducting trace-back and trace-out investigations to determine where rodents from confirmed-positive facilities may have been distributed.
CDC currently recommends testing of all persons who report recent or current illness after (1) handling rats from a facility with Seoul virus infection that was confirmed by laboratory testing (either rat or human), or (2) handling rats from a facility that sold rats to a facility with Seoul virus infection. Testing is also offered to persons without illness but (1) who are reporting exposure to rats from a facility with Seoul virus infection that was confirmed by laboratory testing, or (2) who are reporting exposure to rats from a facility that sold rats to a facility with Seoul virus infection but where no illness has been reported.
In general, CDC recommends consideration of hantavirus testing in all persons with symptoms of Seoul virus infection and rat contact, even if the rat was not associated with a facility where a confirmed infection in a rat or human was reported.
In the United States, hantavirus infections in people are notifiable conditions. Healthcare providers who suspect hantavirus infection in a patient should contact their state or local health department.
During early December 2016, a home-based rat breeder in Wisconsin developed an acute febrile illness. During late December 2016, CDC tested a blood specimen from the patient and confirmed that the infection was caused by Seoul virus, a member of the hantavirus family of rodent-borne viruses. A family member who worked with rodents also tested positive for Seoul virus. Both people have recovered. A follow-up investigation of rat breeders who supplied the initial patient’s rats revealed six additional human cases of Seoul virus infections occurring at two Illinois rat-breeding facilities. Of the eight confirmed cases in Wisconsin and Illinois, two were hospitalized. Rats at these facilities have also tested positive for Seoul virus.
Human and animal health officials are working together to trace-back from where infected rodents may have come, and trace-out where potentially infected rodents may have been distributed, and make sure infected rats are not distributed further. Persons at risk of Seoul virus infection due to exposure to infected rats are also being identified. To date, state health officials in Alabama, Arkansas, Colorado, Illinois, Indiana, Louisiana, Michigan, Minnesota, South Carolina, Tennessee, Utah, and Wisconsin have been notified that their residents may have infected rats.
Seoul virus is transmitted from rats to people. People who become infected with this virus often exhibit relatively mild or no symptoms, but some develop HFRS (https://www.cdc.gov/hantavirus/hfrs), which can result in death in approximately 1–2% of HFRS cases. Symptoms include fever, severe headache, back and abdominal pain, chills, blurred vision, redness of the eyes, or rash. HFRS is characterized by a prodromal phase with non-specific symptoms and can progress to hypotension, decreased urine output, and renal failure, which often resolves after a diuretic phase. Coagulopathy and pulmonary edema are rare complications. Laboratory findings include low platelets, elevated white blood cell counts, electrolyte abnormalities, elevated blood urea nitrogen (BUN) and creatinine, and proteinuria.
People can become infected after exposure to aerosolized urine, droppings, or saliva of infected rodents or after exposure to dust from their nests or bedding. Transmission may also occur from rat bites or when contaminated materials are directly introduced into broken skin or onto mucous membranes. The incubation period for humans ranges from 1 to 8 weeks; however, most individuals develop symptoms 1 to 2 weeks after exposure. Seoul virus is not spread from human to human. Infected rats do not become sick but can shed virus for many months.
Seoul virus infection in humans is confirmed by testing for Seoul virus IgM and IgG antibodies or by detection of viral RNA. IgM is commonly detectable within a few days after symptom onset and is detectable for approximately 2 to 3 months. IgG can usually be detected within a week after symptom onset and can remain detectable for years. Viral RNA is often detectable in blood from patients with acute disease. In coordination with state health departments, CDC offers testing for patients suspected of having Seoul virus infection.
There is no specific treatment for Seoul virus infection. Individuals with acute disease should have blood values monitored with laboratory testing, including complete blood count, basic metabolic profile, liver enzymes, and urinalysis. Supportive therapy is a mainstay of care. Care includes careful management of the patient’s hydration, renal function, and electrolyte levels; care also includes maintenance of correct oxygen and blood pressure levels and appropriate treatment of any secondary infections. Dialysis may be required to correct severe fluid overload. Intravenous ribavirin is an investigational drug that can be available on an emergency use basis for severe disease (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm090039.htm).
1. CDC currently recommends laboratory testing for all persons who report recent or current illness after (1) handling rats from a facility with Seoul virus infection that was confirmed by laboratory testing (either rat or human), or (2) handling rats from a facility that sold rats to a facility with Seoul virus infection. Testing is also offered to persons with exposure to rats from a facility with Seoul virus infection that was confirmed by laboratory testing, or to persons with exposure to rats from a facility that sold rats to a facility with Seoul virus infection but where no illness was reported. All testing should be coordinated with the healthcare provider’s local or state health department.
2. Persons with potentially infected rats should not sell, trade, or release their rats. They should contact their state health department with any questions. Healthcare providers should emphasize the importance of safe animal practices with their patients (https://www.cdc.gov/healthypets/pets/small-mammals/petrodents.html).
3. Health care providers may also consider laboratory testing of patients with symptoms suggestive of Seoul virus infection and a history of rat contact, regardless of whether there is known interaction with rats or rat facilities with laboratory confirmed Seoul virus infections.
4. As with all human hantavirus infections, Seoul virus infection is a notifiable disease. Healthcare providers who suspect Seoul virus infection in a patient should report it to their local health department.
5. For laboratory testing inquiries, healthcare providers should contact their state or local health department. Prior approval is required by the state health department.
For More Information:
CDC Seoul virus FAQs: https://www.cdc.gov/hantavirus/outbreaks/seoul-virus/faqs.html
CDC healthy pets website: https://www.cdc.gov/healthypets/pets/small-mammals/petrodents.html

Posted Feb 1 Delete Mar 15, 2017
UMass Dartmouth has openings for many faculty positions - Professor, Associate, and Assistant Professors as well as clinical track professors. Please look at our website for a full description of each position. I would appreciate it if you could forward to anyone who you think might be interested.
Posted Jan 10, 2017   delete March 4, 2017

Dear Colleagues, I wanted to share information about a new RFA from the EPA to investigate life-long environmental factors influencing health outcomes in later stage of life, called “Total Environment”.  Public nonprofit institutions/organizations (includes public institutions of higher education and hospitals) and private nonprofit institutions/organizations (includes private institutions of higher education and hospitals) located in the U.S., state and local governments, Federally Recognized Indian Tribal Governments, and U.S. territories or possessions are eligible to apply. The deadline for applications is approaching quickly-- March 2, 2017https://www.epa.gov/research-grants/using-total-environment-framework-built-natural-social-environments-assess-life-long

Catalog of Federal Domestic Assistance (CFDA) Number: 66.509
Solicitation Opening Date: December 2, 2016
Solicitation Closing Date: March 2, 2017, 11:59:59 pm Eastern Time
The U.S. Environmental Protection Agency (EPA), through its Science to Achieve Results (STAR) program, seeks applications for research on how pollution affects human health in the context of the total environment – built, natural, and social environments interacting together with inherent characteristics and interactions. Proposed research should develop and test innovative models or impact assessment approaches to examine causal relationships of chemical pollutants and health effects with modifying interactions among the variables representing all of the major stressors and factors involved in a person’s life. Proposals that integrate a diverse field of disciplines (social science, economics, epidemiology, engineering, environmental science, biology, statistics, toxicology, chemistry, etc.) to address the complexity of the total environment research problem are highly recommended.

This solicitation provides the opportunity for the submission of applications for projects that may involve human subjects research.  Human subjects research supported by the EPA is governed by EPA Regulation 40 CFR Part 26 (Protection of Human Subjects).  This includes the Common Rule at subpart A and prohibitions and additional protections for pregnant women and fetuses, nursing women, and children at subparts B, C, and D.  Research meeting the regulatory definition of intentional exposure research found in subpart B is prohibited by that subpart in pregnant women, nursing women, and children.  Research meeting the regulatory definition of observational research found in subparts C and D is subject to the additional protections found in those subparts for pregnant women and fetuses (subpart C) and children (subpart D).  All applications must include a Human Subjects Research Statement (HSRS, as described in Section IV.C.5.c of this solicitation), and if the project involves human subjects research, it will be subject to an additional level of review prior to funding decisions being made as described in Sections V.C and V.D of this solicitation.

Guidance and training for investigators conducting EPA-funded research involving human subjects may be obtained here:
Basic Information about Human Subjects Research
Basic EPA Policy for Protection of Subjects in Human Research Conducted or Supported by EPA

In addition to regular awards, this solicitation includes the opportunity for early career awards. The purpose of the early career award is to fund research projects smaller in scope and budget by early career PIs.  Please see Section III of this Request for Applications (RFA) for details on the early career eligibility criteria.

Award Information:
Anticipated Type of Award: Grant or Cooperative Agreement
Estimated Number of Awards: 5 regular and 5 early-career awards
Anticipated Funding Amount: Approximately $7 million total for all awards
Potential Funding per Award: Up to a total of $800,000 for regular awards and $600,000 for early career awards, including direct and indirect costs, with a maximum duration of four years.
Cost-sharing is not required. Proposals with budgets exceeding the total award limits will not be considered.

Eligibility Information:
Public nonprofit institutions/organizations (includes public institutions of higher education and hospitals) and private nonprofit institutions/organizations (includes private institutions of higher education and hospitals) located in the U.S., state and local governments, Federally Recognized Indian Tribal Governments, and U.S. territories or possessions are eligible to apply. Special eligibility criteria apply to the early career award portion of this RFA. See full announcement for more details.

Posted Jan 10, 2017  delete March 7, 2017
Deadline: March 6, 2017 at 12pm Eastern
The 2017 Joanne Angle Investigator Award provides funding for research investigating public health related to eye health and safety. Applications will be accepted in the following priority areas in adult vision, children’s vision, or eye injury:

·        Burden/economic aspects of eye disease/vision loss on society

·        Best practices to integrate vision screening/follow up care to system care access

·        Vision program effectiveness/evaluation

All research grants need to promote the core mission of Prevent Blindness – preventing blindness and preserving sight. Basic laboratory science research will not be supported under this program. Only applications with investigators and projects based in the United States or Canada will be accepted. Please note preference will be given in 2017 to public health research that relates to AMD and/or glaucoma.

The deadline for the fourteenth annual Joanne Angle Investigator Award is March 6, 2017 at 12pm Eastern. Grants are for a one-year period, up to $25,000, reviewed by a panel of scientists, and commence on July 1, 2017.For more information, visit: http://www.preventblindness.org/investigator-awards. Contact Nita Patel Sinha, Prevent Blindness Director of Public Health at 312-363-6019 or npatelsinha@preventblindness.org with any questions.

The National Cancer Institute (NCI) recently announced two companion Funding Opportunity Announcements on reducing overscreening for cancer among older adults.  We would like to share the announcements with your list servs.

Posted Jan 10, 2017    delete June, 2017

Mark your calendars! The 2017 Omaha System International Conference: A Key to Practice, Documentation, and Information Management will be held April 20-22, 2017 in Eagan, Minnesota. More details are on www.omahasystem.org/conferences.html. The school host will be the Helen and Arthur E. Johnson Beth-El College of Nursing and Health Sciences, University of Colorado, Colorado Springs, Colorado. The calls for award nominations and poster abstracts have just been announced. Start planning your responses and see Conferences for details!

Trends & Topics Archive